vs
Side-by-side financial comparison of Molson Coors Beverage Company (TAP) and Zoetis (ZTS). Click either name above to swap in a different company.
Molson Coors Beverage Company is the larger business by last-quarter revenue ($2.7B vs $2.4B, roughly 1.1× Zoetis). Zoetis runs the higher net margin — 25.3% vs 5.5%, a 19.7% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs 2.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $-212.9M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -15.8%).
Molson Coors Beverage Company is a Canadian-American multinational drink and brewing company headquartered in Chicago, Illinois and Montreal, Quebec.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
TAP vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.7B | $2.4B |
| Net Profit | $150.1M | $603.0M |
| Gross Margin | 33.0% | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 5.5% | 25.3% |
| Revenue YoY | 2.0% | 3.0% |
| Net Profit YoY | 25.0% | 3.8% |
| EPS (diluted) | $0.80 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.7B | — | ||
| Q4 25 | $3.1B | $2.4B | ||
| Q3 25 | $3.5B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $2.7B | $2.2B | ||
| Q4 24 | $3.2B | $2.3B | ||
| Q3 24 | $3.6B | $2.4B | ||
| Q2 24 | $3.8B | $2.4B |
| Q1 26 | $150.1M | — | ||
| Q4 25 | $238.3M | $603.0M | ||
| Q3 25 | $-2.9B | $721.0M | ||
| Q2 25 | $428.7M | $718.0M | ||
| Q1 25 | $121.0M | $631.0M | ||
| Q4 24 | $287.8M | $581.0M | ||
| Q3 24 | $199.8M | $682.0M | ||
| Q2 24 | $427.0M | $624.0M |
| Q1 26 | 33.0% | — | ||
| Q4 25 | 31.0% | 70.2% | ||
| Q3 25 | 33.7% | 71.5% | ||
| Q2 25 | 34.3% | 73.6% | ||
| Q1 25 | 31.6% | 72.0% | ||
| Q4 24 | 32.0% | 69.5% | ||
| Q3 24 | 33.4% | 70.6% | ||
| Q2 24 | 34.6% | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 10.4% | 31.9% | ||
| Q3 25 | -98.5% | 37.0% | ||
| Q2 25 | 15.6% | 36.7% | ||
| Q1 25 | 6.9% | 36.5% | ||
| Q4 24 | 12.0% | 31.6% | ||
| Q3 24 | 12.5% | 36.6% | ||
| Q2 24 | 15.6% | 33.0% |
| Q1 26 | 5.5% | — | ||
| Q4 25 | 7.6% | 25.3% | ||
| Q3 25 | -84.0% | 30.0% | ||
| Q2 25 | 11.5% | 29.2% | ||
| Q1 25 | 4.5% | 28.4% | ||
| Q4 24 | 8.9% | 25.1% | ||
| Q3 24 | 5.5% | 28.6% | ||
| Q2 24 | 11.1% | 26.4% |
| Q1 26 | $0.80 | — | ||
| Q4 25 | $1.32 | $1.37 | ||
| Q3 25 | $-14.79 | $1.63 | ||
| Q2 25 | $2.13 | $1.61 | ||
| Q1 25 | $0.59 | $1.41 | ||
| Q4 24 | $1.39 | $1.29 | ||
| Q3 24 | $0.96 | $1.50 | ||
| Q2 24 | $2.03 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $382.6M | — |
| Total DebtLower is stronger | $3.8B | — |
| Stockholders' EquityBook value | $10.3B | $3.3B |
| Total Assets | $22.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.38× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $382.6M | — | ||
| Q4 25 | $896.5M | — | ||
| Q3 25 | $950.2M | $2.1B | ||
| Q2 25 | $613.8M | $1.4B | ||
| Q1 25 | $412.7M | $1.7B | ||
| Q4 24 | $969.3M | $2.0B | ||
| Q3 24 | $1.0B | $1.7B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | $3.8B | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $6.2B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.2B | — | ||
| Q2 24 | $7.0B | — |
| Q1 26 | $10.3B | — | ||
| Q4 25 | $10.2B | $3.3B | ||
| Q3 25 | $10.3B | $5.4B | ||
| Q2 25 | $13.4B | $5.0B | ||
| Q1 25 | $13.1B | $4.7B | ||
| Q4 24 | $13.1B | $4.8B | ||
| Q3 24 | $13.3B | $5.2B | ||
| Q2 24 | $13.2B | $5.0B |
| Q1 26 | $22.4B | — | ||
| Q4 25 | $22.7B | $15.5B | ||
| Q3 25 | $22.9B | $15.2B | ||
| Q2 25 | $26.8B | $14.5B | ||
| Q1 25 | $25.9B | $14.1B | ||
| Q4 24 | $26.1B | $14.2B | ||
| Q3 24 | $26.6B | $14.4B | ||
| Q2 24 | $27.4B | $14.2B |
| Q1 26 | 0.38× | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | $-212.9M | $732.0M |
| FCF MarginFCF / Revenue | -7.8% | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | $893.0M | ||
| Q3 25 | $616.1M | $938.0M | ||
| Q2 25 | $718.3M | $486.0M | ||
| Q1 25 | $-90.7M | $587.0M | ||
| Q4 24 | $494.5M | $905.0M | ||
| Q3 24 | $521.2M | $951.0M | ||
| Q2 24 | $869.2M | $502.0M |
| Q1 26 | $-212.9M | — | ||
| Q4 25 | $357.8M | $732.0M | ||
| Q3 25 | $483.0M | $805.0M | ||
| Q2 25 | $555.0M | $308.0M | ||
| Q1 25 | $-328.0M | $438.0M | ||
| Q4 24 | $383.4M | $689.0M | ||
| Q3 24 | $350.4M | $784.0M | ||
| Q2 24 | $691.7M | $370.0M |
| Q1 26 | -7.8% | — | ||
| Q4 25 | 11.4% | 30.7% | ||
| Q3 25 | 13.9% | 33.5% | ||
| Q2 25 | 14.8% | 12.5% | ||
| Q1 25 | -12.2% | 19.7% | ||
| Q4 24 | 11.8% | 29.7% | ||
| Q3 24 | 9.7% | 32.8% | ||
| Q2 24 | 18.0% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 6.7% | ||
| Q3 25 | 3.8% | 5.5% | ||
| Q2 25 | 4.4% | 7.2% | ||
| Q1 25 | 8.8% | 6.7% | ||
| Q4 24 | 3.4% | 9.3% | ||
| Q3 24 | 4.7% | 7.0% | ||
| Q2 24 | 4.6% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.27× | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | 1.68× | 0.68× | ||
| Q1 25 | -0.75× | 0.93× | ||
| Q4 24 | 1.72× | 1.56× | ||
| Q3 24 | 2.61× | 1.39× | ||
| Q2 24 | 2.04× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TAP
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
